NCT02546310View on ClinicalTrials.gov

Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Alzheimer's Disease
Interventions
DRUG

HTL0009936

DRUG

HTL0009936 matching placebo

Trial Locations (1)

M13 9PT

Neuroscience and Psychiatry Unit, Manchester

All Listed Sponsors
collaborator

P1vital Limited

INDUSTRY

lead

Nxera Pharma UK Limited

INDUSTRY

NCT02546310 - Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects | Biotech Hunter | Biotech Hunter